Search

Begin New Search Topic Infectious Diseases Publication Year within 3 Years

1. Disease Mix and How Economic Freedom Matters for Health Outcomes

Author:
Vincent Geloso, Kelly Hyde, and Ilia Murtazashvili
Publication Date:
03-2023
Content Type:
Working Paper
Institution:
The Cato Institute
Abstract:
We investigate the institutional foundations of public health. We argue that a key distinction in analysis of disease is between diseases of commerce (diseases associated with movement of people and with affluence) and diseases of poverty (primarily noncommunicable diseases that depend on wealth and income). We show that the mix of disease – the ratio of communicable diseases and those associated with longevity to diseases of poverty – increases in economically free countries. We argue that increasing burdens of diseases of commerce reflects the quality of institutions, as those diseases are better than living shorter, brutish lives where diseases of poverty claim many lives. This analysis also highlights an institutional trade‐​off: economically free institutions reduce certain types of disease while contributing to others.
Topic:
Health, Infectious Diseases, Economy, Institutions, and Public Health
Political Geography:
Global Focus

2. Eight Commonsense Actions on Biosafety and Biosecurity

Author:
J. Stephen Morrison and Michaela Simoneau
Publication Date:
11-2023
Content Type:
Policy Brief
Institution:
Center for Strategic and International Studies (CSIS)
Abstract:
Today, there is a shared sense of vulnerability and a shared resolve across political divides to better protect the United States and the world against the accidental release of biological agents (biosafety), deliberate misuse of biological agents (biosecurity), and naturally occurring spillover of dangerous pathogens. Biosafety and biosecurity are critically important areas where individual freedom, ethics, scientific progress, and national security converge. As biological research and discovery accelerate at an unprecedented pace, they generate new risks that must be managed responsibly. The CSIS Bipartisan Alliance for Global Health Security’s Working Group on R&D Innovation advocates select, commonsense actions to strengthen U.S. and global biosafety and biosecurity: clarify U.S. policies and policy leadership within the White House; increase financial and diplomatic investments; update the rules around synthetic products and viral discovery work; and invest in research on basic lab protections and the new risks of artificial intelligence. Together, these timely, affordable steps can attract broad political support and promote a safer, more secure, and more innovative global bioeconomy.
Topic:
Security, Defense Policy, Infectious Diseases, Biosecurity, COVID-19, and Global Health
Political Geography:
Global Focus

3. Lessons from the Coronavirus Pandemic: Leveraging Biotechnology to Tackle Infectious Diseases in India

Author:
Shruti Sharma
Publication Date:
06-2022
Content Type:
Working Paper
Institution:
Carnegie Endowment for International Peace
Abstract:
In India, the coronavirus pandemic encouraged partnerships between academia and industry, fostered collaboration among competitor companies, and stimulated cooperation within different government departments to leverage biotechnology to develop new test kits, protective equipment, vaccines, and respiratory devices. Despite this collaborative ecosystem, a few stakeholders faced several challenges during different stages of product development including discovery, research and development (R&D), clinical trial, or commercialization of their products. Some of these challenges can be attributed to a lack of an ecosystem that encourages collaborative research in India, limited involvement of private funding entities, a gap between academia and industry where university researchers lack sufficient awareness of the imperatives of industry, and a lack of awareness regarding contemporary applications of biotechnology among the regulatory community. The goal of this paper is to provide all stakeholders and the Indian public an overview of the role that advancements in biotechnology can play in strengthening India’s public health capacity. While the pandemic offered significant opportunities to the scientific community and private players in India to develop medical countermeasures, this paper only illustrates examples that discuss strategies that were adopted to accelerate the development of diagnostics and vaccines in the country. It further elucidates the challenges, both regulatory and funding, that some stakeholders faced in introducing new diagnostics and vaccines into the market during the pandemic. The paper argues that it is important for India to adopt a systematic approach to sustain the collaborative ecosystem that was cultivated during the pandemic. It further provides a brief assessment of the policies that regulate vaccines and diagnostic kits in India and the scope of enhanced and better implementation in the future. The paper also suggests strategies to maintain a continuous flow of investment to sustain research, streamline the regulatory infrastructure to minimize ambiguities regarding product approvals, and foster multistakeholder collaboration to create a sustainable research and innovation ecosystem that can be leveraged during health emergencies in the future.
Topic:
Infectious Diseases, Public Health, COVID-19, and Biotechnology
Political Geography:
South Asia and India